Circulating Tumor Cells in Solid Tumors

Quantification and Characterization of Circulating Tumor Cells in Solid Tumors

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03161821

Enrollment

206

Registered

2017-05-22

Start date

2011-12-09

Completion date

2021-02-16

Last updated

2022-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid Tumor, Adult

Brief summary

The purpose of this study is to identify circulating tumor cells in patients with solid tumors. Quantify and characterize these cells, collect patient information in regards to the patient's cancer. Develop a database and a sample repository where future analysis could be done.

Detailed description

The primary purpose of this correlative study is to create a prospective database documenting the quantity and characterization of circulating tumor cells (CTCs) in solid tumor patients as identified by a various laboratory techniques and analyses. The investigators are developing this resource to provide data to achieve the following objectives: 1) correlate CTCs with known prognostic factors, 2) correlate CTCs with burden of disease, 3) evaluate the ability of CTCs to be used in the surveillance of disease recurrence, and 4) evaluate CTCs ability to be used as a biomarker for treatment response.

Interventions

OTHERObservational

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age ≥ 18 years of age * Biopsy proven solid tumor malignancy * Seen at UNC Chapel Hill Hospital and Health Care System * Consents to abstraction of their medical records * Signed an institutional review board (IRB)-approved informed consent document for this protocol

Exclusion criteria

* \< 18 years of age * Dementia, altered mental status, incarceration or any psychiatric condition that would prohibit the understanding or rendering of informed consent.

Design outcomes

Primary

Measure	Time frame	Description
Documentation of the Characterization of CTCs from Patients with Solid Tumors	Through study completion, an average of 5 years	Characterization of participants' circulating solid tumor cells
Documentation of the Quality of CTCs from Patients with Solid Tumors	Through study completion, an average of 5 years	Enumeration of participants' circulating solid tumor cells

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026